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AKTIVITI APOPTOSIS DAN PENGEKSPRESAN PROTEIN 
PENGAKTIFAN MITOGEN KE ATAS SEL MAKROFAJ MENCIT J774A.1  
YANG DIJANGKITI KLON BCG REKOMBINAN YANG 
MENGEKSPRESKAN PROTEIN PERMUKAAN TERMINUS C  
MEROZOITE-1 DARIPADA Plasmodium falciparum 
 
ABSTRAK 
 
Apoptosis makrofaj merupakan mekanisme yang berkesan dalam mengawal 
jangkitan intrasel semasa gerak balas imun semulajadi terhadap pelbagai patogen 
termasuk parasit malaria. Kajian ini dijalankan untuk menentukan aktiviti apoptosis 
dan pengekspresan protein pengaktifan mitogen (MAPK) dalam sel makrofaj mencit 
J774A.1 yang dijangkiti klon BCG dan BCG rekombinan (rBCG) yang 
mengekspreskan terminus C protein permukaan merozoite-1 (MSP-1C) daripada 
Plasmodium falciparum selama 48 jam. Pewarnaan nukleus menggunakan Hoest 
33342 menunjukkan bahawa klon rBCG berupaya meningkatkan kondensasi nuklear 
dan peringkat morfologi apoptosis dalam sel makrofaj yang dijangkiti berbanding 
BCG dan LPS. Analisis flow sitometri menggunakan pewarnaan Annexin-V dan PI 
membuktikan bahawa klon rBCG meningkatkan peratusan aktiviti apoptotik awal di 
dalam sel makrofaj mencit yang dijangkiti berbanding sel yang dijangkiti oleh klon 
BCG dan dirangsang dengan LPS. Gerak balas apoptosis yang ditunjukkan ini 
seiring dengan pengurangan pengekpresan protein anti-apoptotik Bcl-2 dan 
peningkatan pengekspresan protein p53. Ujian permeteran warna menunjukkan klon 
BCG berupaya mengekspreskan aktiviti kaspase-1, -3, -8 dan -9 manakala klon 
rBCG hanya mengaktifkan pengekspresan kaspase-1 and -9 di dalam sel makrofaj 
  
xv 
yang dijangkiti,  mencadangkan penglibatan laluan apoptosis mitokondria (intrinsik). 
Tambahan pula, jangkitan klon BCG dan rBCG berupaya merangsang pengekspresan 
protein ekstrasel ERK2 yang lebih tinggi dalam sel yang dijangkiti tetapi 
mengurangkan secara signifikan pengekspresan protein p38 dan JNK, yang 
menunjukkan penglibatan sesetengah MAPK dalam aktiviti apoptosis makrofaj yang 
dijangkiti.  Sebagai kesimpulan, kedua-dua klon BCG dan rBCG berupaya 
meningkatkan aktiviti apoptosis di dalam sel makrofaj mencit, J774A.1. Mekanisme 
ini adalah penting untuk menyingkirkan patogen seperti parasit malaria semasa 
aktiviti fagositosis makrofaj. Walaubagaimanapun, klon rBCG menunjukkan aktiviti 
apoptosis yang lebih tinggi berbanding klon BCG.  
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APOPTOSIS ACTIVITY AND MITOGEN ACTIVATED PROTEIN KINASE 
EXPRESSION OF THE MOUSE MACROPHAGE CELL LINE J774A.1 
INFECTED WITH A RECOMBINANT BCG EXPRESSING THE C-
TERMINUS OF MEROZOITE SURFACE PROTEIN-1 OF Plasmodium 
falciparum 
 
ABSTRACT 
 
Macrophage apoptosis exerts an efficient mechanism in controlling intracellular 
infection during innate immune response against various pathogens including malaria 
parasites. This study was carried out to determine the apoptosis activity and mitogen 
activated protein kinase (MAPK) expression in mouse macrophage cell line J774A.1  
infected with a Mycobacterium bovis bacille Calmette-Guerin (BCG) clone and a 
recombinant BCG (rBCG) clone expressing the C-terminus of merozoite surface 
protein-1 (MSP-1C) of Plasmodium falciparum for 48 hours. The nuclear staining 
with Hoechst 33342 showed that the rBCG clone was capable of increasing the 
nuclear condensation and morphological stages of apoptosis in the infected cells 
compared to the BCG-infected cells and the LPS-stimulated cells. The flow 
cytometric analysis using Annexin-V and PI staining confirmed that the rBCG clone 
significantly increased the percentage of early apoptotic activity in the infected 
macrophage higher than the one stimulated by the parent BCG clone and LPS. This 
apoptotic response corresponded with the reduction of the anti-apoptotic Bcl-2 
protein expression and higher p53 expression. The colorimetric assay demonstrated 
that the BCG clone is capable of stimulating higher production of caspase-1, -3, -8 
and -9 while the rBCG clone only stimulated the expression of caspase-1 and -9 in 
  
xvii 
the infected macrophages, suggesting the involvement of mitochondrial-mediated 
(intrinsic) pathway of apoptosis. In addition, an infection with BCG and rBCG 
clones stimulated higher extracellular signal-regulated kinase 2 (ERK2) protein 
expression in the infected cells but significantly reduced the expression of p38 and c-
jun N-terminal kinase (JNK) proteins, suggesting the involvement of certain MAPK 
in the apoptosis activity of the infected macrophages. In conclusion, both the BCG 
and rBCG clones are capable of inducing macrophage apoptosis activity in the 
mouse macrophage cell line J774A.1. This mechanism is important for the 
elimination of pathogens such as malaria parasite during the phagocytosis activity of 
macrophage. However, the rBCG clone showed higher apoptosis activity than those 
produced by the parent BCG clone. 
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CHAPTER ONE 
INTRODUCTION 
 
1.1 Study background 
 
Malaria remains the public health concerns owing to the high rate of mortality and 
morbidity (Wiwanitkit, 2011). It annually affects millions of people throughout the 
world, especially older people and pregnant ladies. Mostly, children under the age 
five years are vulnerable to life-threatening anaemia and cerebral malaria (World 
Health Organization, 2015). The obligate intracellular parasite, Plasmodium is the 
causative agent of malaria disease. The infection is transmitted to humans through 
the saliva of the female Anopheles mosquitoes (Sinden et al., 2002). Plasmodium 
falciparum causes the most serious pathologies of malaria disease in human due to its 
capability to multiply rapidly in the red blood cells. Infections with this parasite can 
be lethal in the absence of quick detection of the disease (Sinden et al., 2002; Snow 
et al., 2005; Ministry of Health Malaysia, 2014; World Health Organization, 2015).  
 
The development of a safe and effective vaccine that elicits lasting immune 
responses against malaria has been a major agenda for controlling the disease due to 
the spread of drug-resistant parasites and insecticide-resistant mosquitoes in many 
parts of the world (Brogdon et al, 1998; Phillips, 2001; Cravo et al., 2015). The 
clinical symptoms and pathologies associated with malaria occur during the blood 
stage infection. At this stage, the parasites express various antigens such as AMA1, 
EBA175 and MSP1. Among these, the 19 kDa C-terminus of the merozoite surface 
protein-1 (MSP-119) or also known as MSP-1C has been extensively studied as a 
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blood-stage malaria vaccine candidate. A previous study showed that antibodies 
produced against the MSP-1C have been reported to be associated with protection 
from symptomatic malaria disease (Wan Omar et al., 2007).  
 
Mycobacterium bovis bacilli Calmette-Guerin (BCG) is the only vaccine used for 
tuberculosis. It represents one of the most promising live vectors for the delivery of 
foreign antigen to the human immune system, including malaria parasites (Bloom, 
1989). Previously, our group has constructed a recombinant BCG clone that 
expresses the MSP-1C of Plasmodium falciparum (Nurul et al., 2010). Our 
constructed vaccine represents a promising candidate to prevent malaria infection by 
inducing appropriate humoral and cellular immune responses in mice. The vaccine 
candidate is also capable of stimulating the production of pro-inflammatory 
cytokines as tumor necrosis factor (TNF-α), interleukin-1β (IL-1β) and nitric oxide 
(NO) and the expression of toll-like receptors in mouse macrophage cell line 
J774A.1 better than the parent BCG clone. Indeed, the previous finding had 
demonstrated that the phagocytic activity of macrophage infected with the rBCG 
clone was increased, resulting in a significant reduction of macrophage viability as 
well as the viability of the rBCG clone itself (Rapeah et al., 2010).  
 
1.2 Problem statement 
 
The rBCG clone expressing MSP-1C antigen was capable to stimulate higher 
production of cytokines, nitric oxide and iNOS in mouse macrophage but reduced the 
viability of the cells (Rapeah et al., 2010). We assumed that this phenomenon 
involved macrophage apoptosis activity due to the fact that the pro-inflammatory 
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response of macrophage induced by BCG was associated with apoptosis activity 
(Keane et al., 2000; Riendeau & Kornfeld, 2003; Vanzembergh et al., 2011) and 
MAPK expression (Cheung et al., 2009). However, information on the ability of the 
rBCG clone to induce apoptosis activity in macrophage during innate immune 
response is still lacking and requires more study. 
 
1.3 Rationale of the study 
 
Macrophage apoptosis and MAPK expression is an essential mechanism which 
exerts protective effects against mycobacteria during innate immune response 
(Schorey et al., 2003; Raja, 2004; Briken et al., 2008). A previous study has shown 
that the rBCG clone expressing the MSP-1C of Plasmodium falciparum was capable 
of stimulating the production of a strong pro-inflammatory response such as TNF-α, 
IL-1β and NO in mouse macrophage cell line J774A.1. We hypothesized that this 
phenomenon involves macrophage apoptosis mechanism and MAPK activation. To 
prove this hypothesis, this study was carried out to evaluate the ability of the vaccine 
candidate to stimulate macrophage apoptosis as well as the signaling pathway 
involved in this event. The information about these mechanisms will assist in the 
development of an efficient vaccine against malaria parasite (Jo et al., 2007). 
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1.4 Objectives of the study 
1.4.1 General objective 
 
The general objective of this study was to investigate the apoptosis activity and 
MAPK expression in mouse macrophage cell line J774A.1 infected with parent BCG 
clone and rBCG clone expressing the MSP-1C of Plasmodium falciparum. 
 
1.4.2 Specific objectives 
 
1. To determine the viability of J774A.1 mouse macrophage cells infected with 
BCG and rBCG clones. 
2. To determine the apoptosis activity in mouse macrophage cell line J774A.1 
infected with BCG and rBCG clones. 
3. To determine the expression of p53, Bcl-2 and Bax in mouse macrophage cell 
line J774A.1 infected with BCG and rBCG clones. 
4. To determine the caspase activity in mouse macrophage cell line J774A.1 
infected with BCG and rBCG clones. 
5. To determine the expression of MAPK protein in mouse macrophage cell line 
J774A.1 infected with BCG and rBCG clones. 
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Preparation of BCG and 
rBCG clones 
Preparation of mouse 
macrophage cell line J774A.1 
Infection of mouse macrophage cell line J774A.1 with BCG and rBCG 
clones at a multiplicity of infection (MOI) of 1:20 for 48 hours 
Expression of 
p53, Bcl-2, Bax 
MAPK 
activities 
Caspase-1, -3, -8 
and -9 activities  
ERK 
protein  
Cell viability 
assay 
JNK 
protein  
Apoptosis 
activity 
Nuclear 
staining 
Annexin-V 
and PI stain 
p38 
protein  
Figure 1.1: Flow chart of the study. 
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 History of malaria 
 
Malaria is an ancient disease which was mostly described in a Chinese document, 
clay tablets from Mesopotamia, Egyptian papyri and Hindu texts before the Christian 
era (B.C.E.) (Bruce-Chwatt, 1988). The clinical descriptions of malarial fever were 
first demonstrated by Hippocrates in about 400 B.C.E. In 1880, Charles Louis 
Alphonse Laveran detected live microscopic bodies in blood of malaria patient and 
suggested it as the malaria parasite. All claims of various parasites causing malaria 
were verified after the development of the staining method using Eosin and 
Methylene Blue by Dimitri Romanowsky in 1891 (Cox, 2010). In 1896, MacCallum 
from Johns Hopkins Medical School found the sexual cycle of the malaria parasite 
(MacCallum, 1987). In 1902, Ronald Ross found that infected mosquitoes were 
accountable for transmission of malaria in 1897 (Jarcho, 1984; Hoffman et al., 
1999). Between 1898 and 1900, an Italian group revealed the sporogony of 
Plasmodium falciparum in Anopheles mosquitoes (Dobson et al., 1999). In 1912, the 
asexual cycle of Plasmodium falciparum in vitro was first cultivated by C. C. Bass 
and Foster M. Johns in human blood, but limited to a few initial maturation cycles 
(Kreier, 1980). Later in 1976, continuous culture of Plasmodium falciparum in a 
medium of red blood cells was successfully done by William Trager and it is a 
starting point of discovery of vaccine for malaria (Trager & Jensen, 1976).  The first 
synthetic Spf66 vaccine for Plasmodium falciparum infection was developed by a 
Colombian Biochemist, Dr. Manuel Elkin Patarroyo in 1987 (Graves et al., 2008). 
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2.2 Malaria burden  
2.2.1 Worldwide 
 
Malaria infection is a serious worldwide health issue which contributes to millions of 
deaths. According to the latest estimates in 2015, about 214 million cases of malaria 
and 438 000 malarial deaths were reported (World Health Organization, 2015). 
Globally, approximately 306 000 children before the age of five years are vulnerable 
to get malaria and its developing disease (Heelan et al., 2002; World Health 
Organization, 2015). African Region is the most affected region with malaria burden, 
where an estimated 292 000 cases of malaria deaths were occurred in African 
children. The majority of malaria deaths in the African continent were caused by 
Plasmodium falciparum (World Health Organization, 2015; CDC, 2016). Figure 2.1 
shows areas where malaria transmission occurs.  
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Figure 2.1: Global distribution of malaria transmission risk for 2015. The 
figure is adapted from World Health Organization (2015). 
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2.2.2 Malaysia 
 
In Malaysia, approximately 3923 new cases of malaria infections and nine cases of 
malaria deaths were reported in 2014. These infections comprise of human malaria 
infections and zoonotic malaria infections. Among the human malaria infections, 
Plasmodium vivax accounted most of the malaria infections (8%) followed by 
Plasmodium falciparum (7%) (World Health Organization, 2015). As shown in 
Figure 2.2, malaria infections were usually found in the states of Sabah and Sarawak. 
There were a few cases of malaria infections reported in Peninsular Malaysia 
(Kheong et al., 2010; Rundi et al., 2011; Ministry of Health Malaysia, 2013; World 
Health Organization, 2015). Plasmodium knowlesi, a simian malaria parasite that 
infects human was detected in the forested regions of Malaysia especially in Sarawak 
(Singh et al., 2010). These species accounted 38% of the reported cases of malaria in 
2014 (World Health Organization, 2015). It was reported that 61.9% of malaria cases 
were between the ages of 20 to 49 years and the most affected group were in the age 
group of 20 to 29 years (25%). Also, 2.5% of all malaria cases were in children 
below the age of five. Malaria predominantly affected male (78.2%) compared with 
female (21.8%). Approximately, 8.5% of the female patients who suffered malaria 
infection were pregnant women (Ministry of Health Malaysia, 2013).  
 
.  
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Figure 2.2:  Distribution of confirmed malaria cases (per 1000 population). 
The figure is adapted from the World Health Organization (2015). 
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2.3 Malaria parasites  
2.3.1 Plasmodium species 
 
Plasmodium is the causative agent of malaria infection, which is transmitted through 
the saliva of female Anopheles mosquitoes to human (Levinsion, 2008). Five species 
of Plasmodium that infect human are Plasmodium falciparum, Plasmodium 
malariae, Plasmodium vivax, Plasmodium knowlesi and Plasmodium ovale (Mendis 
et al., 2001; Singh et al., 2004; Collins & Jeffery, 2005; Snow et al., 2005; Collins & 
Jeffery, 2007). The various species of parasites are classified based on their disease’s 
severity (Wipasa et al., 2002) and have different microscopic appearances during the 
blood stage life cycle. Among the five species, the most life-threatening species is 
Plasmodium falciparum due to its ability to multiply rapidly in the patient’s blood 
which contributes to severe anaemia in the patient. Plasmodium falciparum infection 
may lead to death if untreated (Sinden & Gilles, 2002; Snow et al., 2005).  
 
2.3.2 Life cycle of Plasmodium 
 
The mode of infection and developmental stages in the hosts are similar in all human 
malaria parasites. As illustrated in Figure 2.3, the complex life cycles of Plasmodium 
consist of two major stages; asexual development in the human host and sexual 
development in the mosquito vector (Gilles, 1997).  While infected mosquitoes draw 
its blood meal, the spindle-shaped sporozoites are injected into the human 
bloodstream through their salivary glands. Mostly, this liver stage is asymptomatic 
here the majorities of sporozoites invade hepatocytes of liver and multiply in it 
(Sherman, 1998; Amino et al., 2006).  
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.  
 
 
 
 
 
Figure 2.3: Life cycle of Plasmodium falciparum. The figure is adapted from 
Cowman et al. (2012). 
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The maturation and differentiation of sporozoites into merozoites inside hepatocytes 
take place within one to two weeks. About 30,000 merozoites are free to leave from 
ruptured liver cells into the blood circulation. Then, the newly formed merozoites 
initiate asexual multiplication cycle where they invade red blood cells in the 
bloodstream. During the asexual blood stage, the formed merozoites develop into 
trophozoites and then, turn into schizonts. Every schizont produces 10,000 to 30,000 
merozoites which then infect other erythrocytes to restart a new cycle (Sherman, 
1998; Ginsburg et al., 1990; Amino et al., 2006).  
 
The sexual cycle is initiated when some of the released merozoites from infected 
RBC turned into mature gametocytes. The mature gametocytes circulate in the 
human bloodstream and can be ingested by the mosquitoes. The maturation process 
of gametocytes continues in the midgut of mosquito where the union of gametes 
results in the formation of zygotes. The zygotes become motile forms of ookinete 
which can pass through the midgut wall of mosquito and then, grows into oocysts. 
Over time, the oocysts expand and rupture which lead to the formation of 
sporozoites. The released sporozoites are transmitted to infect new human being 
through the mosquito salivary gland (Bousema & Drakeley, 2011).  
 
 
 
 
  
14 
2.4 Clinical symptoms and manifestations 
 
The person infected with malaria parasites remains asymptomatic during the liver 
stage of parasite life cycle. The infected person will suffer nonspecific symptoms of 
uncomplicated malaria such as fever, headache and chills when infected erythrocyte 
ruptured to release merozoites. During the erythrocytic cycle, severe forms of 
malaria pathologies including cerebral anaemia (coma), hypoglycemia, metabolic 
acidosis, renal failure and severe anaemia were observed (Miller et al., 1994; 
Lamikanra et al., 2007; Haldar & Mohandas, 2009). The majority complication of 
severe malaria cases such as kidney failure and coma contribute to deaths. 
Thrombocytopenia and hepatosplenomegaly are other complications of severe 
malaria which occur in infected people especially in the children (Sinden & Gilles, 
2002; Vivas et al., 2008).  
 
2.5 Pathogenesis of malaria 
 
Sequestration is a key event of pathogenesis of malaria leading to severe malaria. 
This event occurred when infected RBC from blood circulation binds to the 
endothelium of capillaries and venules of the host cell (Fayard et al., 2010). 
Sequestration can be characterized by the blockage of blood vessel and impaired 
oxygen supply. This phenomenon can happen in vital organs and leads to organs 
dysfunction (Turner et al., 1994).  The adhesion of infected RBC in endothelium of 
the brain results in cerebral malaria (Miller et al., 1994; Wassmer et al., 2003). 
Furthermore, the occurrence of cerebral malaria is mediated by the production of NO 
and other pro-inflammatory cytokines (Clark et al., 1992). Sequestration events in 
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intervillous spaces of placenta also cause complications in infants including low birth 
weight and infant anaemia (Rogerson et al., 2007).  
 
Another pathogenesis of malaria is rosetting, described as when the infected RBC 
adheres to the uninfected RBC leading to the formation of rosettes. This phenomenon 
contributes to severe form of microvascular disease (Udomsangpetch et al., 1989; 
Chen et al. 2000). In addition, glycosyl-phosphatidyl inositol-anchored protein of 
Plasmodium falciparum plays a significant role in the pathogenesis of severe malaria 
through induction of pro-inflammatory response in mammalian hosts (Schofield et 
al., 1993; Arrighi & Faye, 2010). 
 
2.6 Prevention and treatment of malaria 
 
Antimalarial drugs such as chloroquine, mefloquine, quinine and artemisinin have 
been widely used in the treatment of malaria. Due to the complexity of malaria 
parasites, these drugs only destroy specific morphological stages of malarial life 
cycle (Bjorkman et al., 1990; Heelan et al., 2002; Cravo et al, 2015). Thus, the 
combinations of artemisinin derivatives with other drugs (mefloquine, piperaquine 
and amodiaquine) were used for malaria treatments in order to control malaria 
symptoms as well as reduce parasite density (Price, 2000). Moreover, the emergence 
of drug-resistant parasite provides great challenges to the treatment of malaria 
(Bjorkman et al., 1990; Cravo et al, 2015).  
 
Together with treatments of malaria, long term mosquito abatement was 
implemented for reduction of infected mosquito (vector) population. Several 
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strategies such as elimination of mosquito breeding sites and the use of insecticides 
were applied in many parts of the world to prevent malaria parasites transmission 
from mosquitoes to human (Heelan et al., 2002). In addition, insecticide-treated nets 
have been used to protect human from the bite of infected mosquito as well as kill 
sporozoite-infected mosquito. Still, this strategy is partially effective because some 
of the mosquitoes have developed into insecticide-resistant mosquitoes (Heelan et 
al., 2002; Bockarie et al., 2006). 
 
2.7 Malaria vaccine development 
2.7.1 Different targets of malaria vaccine 
 
The development of a malaria vaccine is a public agenda since the widespread of the 
drug-resistant malaria parasites and insecticide-resistant mosquitoes gave a difficulty 
in combating malaria infection (Phillips, 2001). Various malaria vaccine candidates 
have been developed against the diverse stages of life cycle such as asexual blood 
stage, pre-erythrocytic stage and transmission-blocking stage (Wipasa et al., 2002; 
Hill, 2011). Figure 2.4 shows malaria vaccine candidate antigens. 
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Figure 2.4: Malaria vaccine candidate antigens. All the candidate antigens for 
Plasmodium falciparum are superimposed on the Plasmodium life cycle, to indicate 
the category of malaria vaccine being developed and the life cycle stage targeted. 
Antigens indicated in bold are those that are currently being evaluated in pre-clinical 
trials or have entered at least Phase 1 clinical trials according to the World Health 
Organization malaria vaccine rainbow tables. This figure is adapted from the World 
Health Organization (2013). 
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The vast majority of malaria vaccine candidates are blood stage vaccines. These 
vaccines target merozoites antigen that is involved during the invasion of RBCs 
(Ellis et al, 2010; Birkett et al., 2013; Riley et al., 2013). The purpose of these 
vaccines is to reduce or prevent severe form of malaria complications that were 
developed from RBC invasion at the blood stage. Among these vaccines, apical 
membrane antigen 1 (AMA1) and merozoite surface protein 1 (MSP1) are leading 
vaccine candidates that have been extensively studied (Ellis et al, 2010). 
 
Pre-erythrocytic vaccines are potential vaccine candidates that target sporozoites of 
Plasmodium during pre-erythrocytic stage. The reduction of sporozoites can 
indirectly reduce the release of merozoites into the blood circulation, preventing the 
progression of blood-stage disease (Bejon et al., 2005; Duffy et al., 2012). Among 
the pre-erythrocytic vaccines, RTS,S vaccine is the first malaria vaccine candidate 
that enters Phase III trials. Vaccination with RTS,S induce antibodies against the 
circumsporozoite protein (CSP) of Plasmodium falciparum. However, this vaccine 
was partially effective in treating severe malaria complication (Agnandji et al., 2012; 
Ajua et al., 2015; Moorthy et al., 2015).  
 
Meanwhile, malaria transmission-blocking vaccines target gametocytes and oocyst at 
the sexual life cycle. Although these vaccines cannot prevent clinical illness of 
malaria, but these vaccines prevent human-to-mosquito transmission and greatly 
assist in the elimination of malaria infections (Bousema & Drakeley, 2011; Birkett et 
al., 2013; Riley et al., 2013; Nunes et al., 2014).   
 
 
  
19 
2.7.2 C-terminus of merozoite surface protein-1 
 
Several parasite proteins have been identified as vaccine candidate antigens that are 
capable to stimulate host’s natural immunity (Doolan et al., 2003; Dutta et al., 2009; 
Hviid, 2010). Among them, the merozoite surface protein 1 (MSP-1) has been 
extensively studied as the candidate antigen during the blood stage cycle. This 
antigen can be found in human malaria parasites (Matsumoto et al., 1998).  During 
the cleavage process of MSP-1, only COOH-terminal 19-kD fragment of MSP-1 
(MSP-119) remains on the surface of merozoite during RBC invasion (Blackman et 
al., 1990; Blackman et al., 1991).  In vitro study demonstrated that antibodies 
produced in response of MSP-119 inhibited RBC invasion by merozoite (Blackman et 
al., 1990). In addition, protective immunity induced by MSP-1 was observed in the 
Plasmodium yoelii model (Holder et al., 1981; Burns et al., 1989; Daly et al., 1993). 
Also, that vaccination with MSP-1 of Plasmodium falciparum protects non-human 
primate from the malaria infection (Herrera et al., 1990).  
 
2.7.3 Recombinant BCG as a potential vaccine candidate 
 
Mycobacterium bovis bacille Calmette-Guerin (BCG) is a non-pathogenic and 
attenuated strain of Mycobacterium bovis. BCG has been widely used as a 
tuberculosis (TB) vaccine because it preserves the immunogenic characteristics of 
TB (Britton & Palendira, 2003). Since it offers low toxicity, adjuvant potential and 
long-lasting immunity, this vaccine has been extensively used as a vaccine vehicle 
for the presentation of protective antigens in the development of new live 
recombinant vaccines (Bloom, 1989; Stover et al., 1991). However, mice immunized 
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with BCG only stimulate nonspecific resistance against malaria infection (Clark et 
al., 1976; Murphy et al., 1981; Lussow et al., 1990). Thus, the combination of BCG 
and MSP-1C is a reasonable approach in order to enhance, broaden and extend 
immune protection against a range of diseases including malaria (Magalhaes et al., 
2008; Stover et al., 1994). 
 
Previously, a rBCG expressing the synthetic MSP-1C of Plasmodium falciparum was 
constructed (Nurul et al., 2010).  The vaccine was capable of stimulating a strong 
inflammatory action in macrophages by enhancing its phagocytic activity and 
secretion of pro-inflammatory cytokines (TNF-α, IL-1β, NO). The vaccine candidate 
was also able to reduce the viability of infected macrophages (Dhaniah et al., 2014). 
  
2.8 Immunity against malaria infection 
2.8.1 Innate immunity 
 
Innate immunity is an efficient way to control early infection of infectious agents 
such as mycobacteria. Recognition of mycobacteria through toll-like receptors 
(TLRs) leads to the initiation of mitogen-activated protein kinase pathways 
(Medzhitov et al., 2000; Akira et al., 2004; Akira et al., 2006). These mechanisms 
contribute to pro-inflammatory responses which is important in innate host defense 
against various infectious agents (Joyoti et al., 2012). According to Artavanis et al. 
(2003), the secretion of pro-inflammatory cytokines in innate immunity was capable 
to protect mice and humans from erythrocytic malaria. Also, innate immunity plays a 
crucial part in inhibiting the replication of malaria parasites and delays the severe 
complications of malaria disease (Rojas et al., 1999; Artavanis et al., 2003). 
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2.8.2 Macrophage 
 
Antigen-presenting cells such as macrophages, monocytes and dendritic cells are key 
elements of innate immune response. These cells provide a rapid defense mechanism 
to protect the host from invading pathogens (Stevenson, 2004). Among these cells, 
macrophage represents as the main phagocytic cell as the activation of macrophage is 
crucial in innate immune protection against mycobacteria. Macrophages also have 
several functions such as killing pathogenic microorganisms, presenting the antigens 
ingested to T-lymphocytes and removing the cell debris (Fenton et al., 1996; Lee, 
2007). In addition, macrophage infected with mycobacteria triggering the cellular 
events of microbial mechanisms such as the secretion of pro-inflammatory cytokine 
and ligation of pattern recognition receptor. The secretion pro-inflammatory cytokine 
is capable to inhibit the progression of pathogen growth. Meanwhile, ligation of 
pattern recognition receptor avoids the cytopathic effects of invading pathogen 
(Giacomini et al., 2001; Lee at al., 2009).  
 
2.9 Apoptotic cell death 
 
The programmed cell death, apoptosis is an efficient mechanism during the innate 
immune response which limits the release of intracellular pathogens. The 
dissemination of mycobacteria was controlled through sequestration of the pathogens 
within apoptotic bodies (Bailey et al., 2005; Behar et al., 2011). Apoptosis activity 
can be recognized by the preservation of plasma membrane, the shrinkage of cells, 
the presence of apoptotic bodies, the condensation of chromatin and the 
fragmentation of the nucleus. Apoptosis exerts protective activity against 
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mycobacteria by preventing the release of intracellular components. Also, apoptosis 
prevents the dissemination of mycobacteria through sequestering the pathogens 
within apoptotic bodies leading to a reduction in bacterial viability (Behar et al., 
2011). Macrophage acts as a phagocyte which engulfs the apoptotic bodies and 
removed them in order to avoid inflammation and tissue damage (Fadokl et al., 1992; 
Schwartzman et al., 1993; Falasca et al., 1996; Wickman et al., 2012). As shown in 
Figure 2.5, there are several mechanisms associated with apoptosis include the 
accumulation of p53 protein and activation of a caspase-dependent, cytolytic 
pathway (Mitchell et al., 2002).  
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Figure 2.5: Apoptosis signaling pathways. This figure is adapted from Duprez et al. (2009). 
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2.10 Caspase activation 
 
Apoptosis is mediated by caspases enzymes which are known as cysteinyl aspartate-
specific proteases. Caspase-dependent apoptosis can be triggered by two different 
pathways such as death receptor (extrinsic) and mitochondrial (intrinsic) signaling 
pathways (Figure 2.6). The extrinsic signaling pathway is linked to the ligation and 
oligomerization of death receptor by their cognate ligands. The binding of death 
receptor such as tumor necrosis receptor (TNFR) to its cognate ligands (TNF-α) 
result in the activation of upstream caspase-8 (initiator caspase) (Chen et al., 2002). 
These events lead to the activation of downstream caspase-3 (effector caspase) 
triggering apoptosis activity (Lavrik et al., 2012). 
 
As shown in Figure 2.6, the intrinsic pathway is initiated by the permeabilization of 
mitochondria. The disruption of mitochondria causes the release of apoptotic 
proteins. Cytochrome c from mitochondria enters the cytosol and results in the 
formation of apoptosome.  These cellular events initiate the activation of caspase-9 
(initiator caspase) leading to activation of caspase-3 (effector caspase) for apoptosis 
process (Li et al., 1997; Green et al., 2004; Gavathiotis et al., 2011; Yivgi‐Ohana et 
al., 2011). The intrinsic pathway involves the release of Bcl-2 family proteins which 
are crucial regulators of apoptosis. The anti-apoptotic proteins such as Bcl-2, Bcl-w, 
and Bcl-xl play a role in apoptosis inhibition. Meanwhile, pro-apoptotic proteins 
such as Bax, Bak and Bcl-xs promote apoptosis activity (Chipuk et al., 2008; 
Brunelle et al., 2009).  
 
  
